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Abstract
Background: Soil-transmitted helminths and schistosomiasis are mostly prevalent in developing countries due to poor
sanitation and lack of adequate clean water. School-age children tend to be the target of chemotherapy-based control
programmes because they carry the heaviest worm and egg burdens. The present study examines adverse events (AEs)
experienced following co-administration of albendazole and praziquantel to school-age children in a rural area in Kwale
County, Kenya.
Methods: Children were treated with single doses of albendazole and praziquantel tablets and then interviewed using a
questionnaire for post treatment AEs.
Results: Overall, 752 children, 47.6% boys, participated in the study. Their median (interquartile range) age was 12.0 (10.0–
14.0) years. A total of 190 (25.3%) children reportedly experienced at least one AE. In total, 239 cases of AEs were reported
with the most frequent being abdominal pains (46.3%), dizziness (33.2%) and nausea (21.1%). Majority of the reported AEs
(80.8%) resolved themselves while 12.1% and 6.3% were countered by, respectively, self-medication and visiting a nearby
health facility. More girls (60.5%) than boys (39.5%) reported AEs (P= 0.027).
Conclusions: The AEs were mild and transient, and were no worse than those expected following monotherapy. The current
study adds to the evidence base that dual administration of albendazole and praziquantel in school-based mass drug
administration is safe with only mild adverse events noted.
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Introduction
Soil-transmitted helminths (STH) and schistosomiasis are mostly
prevalent in developing countries where poor sanitation and lack
of adequate clean water are commonplace. STH infections are
among the most prevalent infections in the world with around 1.4
billion individuals infected by Ascaris lumbricoides, 1.0 billion by
Trichuris trichiura, and 1.3 billion by hookworms [1]. About 200
million people are estimated to be infected with schistosomiasis
with 170 million living in sub-Saharan Africa while the remaining
30 million live in North Africa, Asia and South America [2]. The
coastal areas of Kenya are highly endemic for urogenital
schistosomiasis and STH [3,4]. Children have the highest
prevalence and intensity of STH and schistosomiasis infections,
but the consequences of chronic infection, such as growth stunting,
anaemia, hepatic/urinary fibrosis, and impaired cognitive devel-
opment, continue to have an effect throughout adulthood [5].
In 2001, during the 54th WHA, the WHO urged its member
states to ensure provision for the regular antihelminthic treatment
of all school-age children living in areas of schistosomiasis and
STH endemicity [2]. Presently, schistosomiasis and STH control
strategies focus on mass administration of praziquantel and
albendazole, with special emphasis on treating school age children
[6]. An integrated approach, against urogenital schistosomiasis
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and STH using praziquantel and albendazole, respectively, has
been shown to be effective at reducing prevalence and intensity of
infections in several countries in sub-Saharan Africa in various
programmes [7,8]. These orally administered drugs are affordable,
efficacious and safe for the large-scale treatment of human
populations [9,10]. Further, they are given as single dose tablets
and are therefore expected to ensure greater compliance [11].
School-aged children tend to be the target of chemotherapy-based
control programmes because they carry the heaviest worm and
egg burdens. This is due, in part, to their hygiene and behavioural
practices, determining higher exposures and rates of acquisition of
infection [12].Treatment of children is also likely to be more
successful in averting the development of subsequent, more serious
disease sequelae because earlier stages of infection-induced
pathology may be reversible if treated promptly [13].
In 2009, a research project to evaluate a pilot schistosomiasis/
STH control programme and its integration with the national LF
elimination programme was established in Kwale District, Kwale
County, Kenya. Kwale has previously been shown to be highly
endemic for urogenital schistosomiasis and STH [14–16]. The aim
of the present study was to determine the safety of co-
administration of albendazole and praziquantel to school-age
children for control of STH and urogenital schistosomiasis.
Methods
Ethical Statement
Permission to conduct the current study, including review and
approval by the Scientific Steering and Ethical Review Commit-
tees, was obtained from Kenya Medical Research Institute
(KEMRI). The district education office, district health office, local
leaders, teachers and parents were informed about the study in the
area. Written informed consent was obtained, from a guardian,
caretaker or a parent, for each of the participants in the study.
Besides, oral informed consent was obtained from the study
participants. No respondent’s identifiers were included in the
dataset used for these analyses. The dataset is available, for free,
upon making a written request to the corresponding author.
Study Site
The study was conducted in Mwaluphamba Location, Matuga
District, Kwale County, Kenya. The district covers an area of
1,043 km2and has an estimated population of 151,978 residents
[17]. The study area was previously described in a related
publication by Njenga et al [14]. Mwaluphamba Location is
situated in a rural setting of Matuga District bordering a drier
Kinango District in the West. The district experiences a bimodal
rainfall pattern with long rains occurring between mid-March and
June while the short rains occur between October and December.
The majority of the residents of the study area practice subsistence
farming.
Study Design and Population
The population involved in the present cross-sectional study
included 752 school-age children from five sentinel schools,
namely; Maponda (161), Miatsani (140), Mirihini (155), Kajiweni
(167) and Mlafyeni (129).
Treatment
In the month of July, 2010, children from the five schools
received the first round of combination therapy. They were treated
with a single dose of praziquantel (PrazitelH, Cosmos Ltd) using
the dose pole method to determine the number of tablets to be
administered to each child [9]. Additionally, the children were
treated for soil-transmitted helminths using a single dose of
albendazole 400 mg tablets (UnibazoleH, Universal Pharmacy (K)
Ltd). The programme, through the teachers, requested parents/
guardians to provide a morning meal to the children on the day
the MDA took place. Further, schoolteachers, who participated in
the distribution of study drugs, were given a one day training
facilitated by district health and education officers who were
assisted by a national team from the Ministries of Health and
Education and the research team from KEMRI.
Data Collection and Statistical Analysis
One week after the administration of the medications, the
children were interviewed for AEs using an interviewer-
administered structured questionnaire. Details of the AEs experi-
enced 48 hours post treatments, if any, were recorded. The
reported AEs were classified as defined in the WHO guidelines
whereby mild AEs were defined as undesirable experiences
associated with use of the antihelmithics but not affecting daily
activities (e.g. playing) whereas moderate AEs were defined as
those affecting performance of daily activities. Severe AEs were
defined as those requiring total rest and/or medication while
serious AEs were defined as those that were life-threatening
requiring admission to hospital [18,19].
Data were entered into a computer using Microsoft Excel and
then exported to IBM SPSS Statistics 19.0 for analyses.
Appropriate descriptive statistics were computed. Chi-square (x2)
test was used to compare proportions. Statistical significance was
set at p, 0.05.
Results
A total of 752 school-aged children, 47.6% of whom were boys,
were interviewed for AEs experienced following administration of
albendazole and praziquantel tablets. Their median age was 12.0
years (interquartile range: 10.0 to 14.0 years) with a majority of
them (70.7%) being in the age category of 10–14 years as shown in
Table 1.
After taking the medications, 190 (25.3%) children reported
experiencing at least one AE as shown in Figure 1. The number of
respondents who experienced one and two AEs were 146 (19.4%)
and 36 (4.8%), respectively. Only eight respondents (1.0%)
experienced more than two AEs.
Table 2 presents the description and frequencies of AEs
reported by the school children interviewed. Overall, 239 cases
of AEs were reported with abdominal pain being the most
commonly reported AE. The other commonly reported AEs
Table 1. Characteristics of the respondents.
Variable Number (n =752) %
Gender
Male 358 47.7
Female 393 52.3
No response 1 0.1
Age category (years)
, 10 76 10.1
10 – 14 532 70.7
.14 144 19.1
doi:10.1371/journal.pone.0088315.t001
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included dizziness, nausea, head ache and vomiting. Of the 239
AEs reported, majority (84.0%) lasted a day or less.
The majority of the reported AEs were mild (166, 69.5%) while
moderate and severe AEs constituted 23.8% (57) and 6.3% (15) of
the total AEs reported respectively (Table 3). All the respondents
who reported having experienced one or more AEs opined that
the AEs were related to the study medications except for one
respondent whose response was unavailable. Majority of the
reported AEs (193, 80.8%) did not involve any intervention
measures to mitigate those undesired events. Only 6.3% cases
were reported to have involved seeking medical attention in a
nearby hospital while 12.1% were countered by self-medication
involving taking painkillers and anti-allergy drugs available in
kiosks as PanadolH (paracetamol) and PiritonH (chlorpheniramine),
respectively.
Gender was significantly associated with AEs with more girls
than boys reporting to have experienced AEs to the study drugs
(60.5% versus 39.5%, P=0.027). Investigations into the age
categories showed that more children in the 10 to 14 years age
category (66.8%) had had adverse reactions as compared to those
in other age categories though this was not statistically significant
(Table 3).
Overall, no AE was rated by the respondents as serious while
only a few AEs were rated as severe (23, 6.5%) as shown in Figure
2. The 23 cases of AEs were reportedly taken to hospital for
treatment though no admissions were done. These severe AEs
were constituted by vomiting (21.1%), stomachaches (11.9%) and
headaches (8.9%).
Table 4 presents the relationship between gender and the type
of AEs. Generally, more AEs were reported by girls than boys
except for drowsiness. Nevertheless, this trend was not significant,
statistically, but for dizziness (30.6% for boys versus 69.4% for
girls, x2= 6.114, df = 1, p = 0.013).
Discussion
A substantial proportion of children (25%) reported having
experienced one or more AEs following co-administration of
Figure 1. Distribution of the number of adverse events
experienced.
doi:10.1371/journal.pone.0088315.g001
Table 2. Description and frequency of reported adverse
events.
Description Number (n =239) %
Nature of adverse event
Abdominal pain 89 37.2
Dizziness 44 18.4
Nausea 40 16.7
Headache 33 13.8
Vomiting 10 4.2
Drowsiness 13 5.4
Urination* 5 2.1
Itching 5 2.1
Duration of adverse events
1 day or less 199 83.3
More than a day 38 15.9
No response 2 0.8
*Polyuria (3) and dysuria (2).
doi:10.1371/journal.pone.0088315.t002
Table 3. Characteristics of the children who experienced
adverse reactions.
Variable No. (n=190) % p-value
Age (years)
,10 17 8.9 0.117
10 – 14 127 66.8
.14 46 24.2
Sex
Male 75 39.5 0.027
Female 115 60.5
doi:10.1371/journal.pone.0088315.t003
Figure 2. Severity of the adverse events.
doi:10.1371/journal.pone.0088315.g002
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albendazole and praziquantel tablets. However, most of these AEs
were mild and resolved within a day or two. The AEs reported in
the current study included gastrointestinal disturbances such as
abdominal pain, nausea and vomiting. Headaches, drowsiness and
dizziness were also reported as AEs. Adoubryn et al [20]
conducted a similar study in Biankouma, Coˆte d’Ivoire and found
the frequency of AEs to be 40.8%, which is higher than in the
current study. In another study, N’Goran et al found 33.3% of
school children treated with praziquantel alone experienced one
side effect AE or more which is also much higher compared to the
present study [21]. A study on the side effects of praziquantel in a
community of western Coˆte d’Ivoire, however, found a lower
prevalence of side effects compared to the current study with only
12.5% of the individuals reporting one or more side effects
24 hours post-treatment [22]. The results of the current study are
discordant with those from a study done in Southern Ethiopia
where 83% of children treated with praziquantel alone com-
plained that they experienced two or more treatment-related
symptoms suggestive of side effects of the drug [23]. The reasons
for the variations in proportions of AEs experienced after
antihelminthic treatment could probably be due to dissimilar
intensities of parasites as well as differences in socio-economic
status, types of foods and environmental conditions associated with
the diverse populations. Nevertheless, all the studies were in
agreement with the current study by rating the side effects as mild.
By and large, the proportion of children who reportedly
experienced AEs is comparable to what has been observed in other
studies involving praziquantel whereby a higher proportion of
respondents are reported to experience AEs as compared to
albendazole. Indeed, a review by Horton (2000), reported that
incidences of side effects associated with albendazole at the doses
used for the treatment of intestinal helminths are very low, mild
and self-limiting with only gastrointestinal side effects occurring
with an overall frequency of just greater than 1% [24]. Side effects
due to praziquantel, however, have been reported to occur in 30–
60% of the patients, but, just like for albendazole, they are also
mild and transient and disappear within 24 hours [21,25,26]. The
most prevalent AE in the present study was abdominal pain
(37.2%), followed by dizziness (18.4%) and nausea (16.7%). Other
researchers have also found abdominal pain to be the most
common AE reported after administration of praziquantel and/or
albendazole. Studies conducted among school children in different
parts of Kenya where intestinal schistosomiasis is endemic also
found abdominal pain to be the most frequently reported AE
following treatment [26,27]. Further, a double-blind placebo-
controlled study involving 11500 children from China, Kenya and
Philippines concluded that AEs due to co-administrations of both
albendazole and praziquantel are no worse than those observed
with praziquantel alone and the main side effects are abdominal
pain and headache [28].
The current study reported no serious life-threatening AEs. In
fact, only 15(6.3%) respondents reported severe AEs while the rest
were either were mild (69.5%) or moderate AEs (23.8%). The
frequencies of side effects and also severity have been loosely
linked to the proportion of the dying parasites and the subsequent
release of their products [27,29]. The abdominal pain may be
related to a direct pharmacologic effect on the parasite, and
possibly to a massive shift or death of worms in the mesenteric
veins, which may lead to congestion and ultimately acute intestinal
colic [29].
Significantly more girls than boys experienced AEs in the
current study. A study by Raso et al using praziquantel alone
reported abdominal pain to occur more frequently in women than
men [17]. The reasons for differences in occurrence of AEs
between males and females is unclear but could be due to
physiological differences.
The current study’s limitations include the unavailability
parasitological data which would have enriched the discussion
since adverse effects are usually related to infection intensity.
Moreover, having such data would allow comparisons with other
published studies in the field. The delay before administering the
interview seems too long, particularly given the age of the children
and this may have lead to recall bias.
Conclusions
Generally, a range of AEs were associated with the current
drugs used in the treatment of schistosomiasis and STH, i.e.,
Table 4. Association between adverse events and gender.
Adverse Event Total(n = 752) Male (n=358) Female (n=393) x2 df P-value
Stomachache
Yes 88 41(46.6%) 47(53.4%) 0.047 1 0.829
No 663 317(47.8%) 346(52.2%)
Headache
Yes 33 13(39.4%) 20(60.6%) 0.948 1 0.330
No 718 345(48.1%) 373(51.9%)
Dizziness
Yes 49 15(30.6%) 34(69.4%) 6.114 1 0.013
No 702 343(48.9%) 359(51.1%)
Vomiting
Yes 10 3(30.0%) 7(70.0%) 1.268 1 0.260
No 741 355(47.9%) 386(52.1%)
Drowsiness
Yes 13 9(69.2%) 4(30.8%) 2.465 1 0.116
No 738 349(47.3%) 389(52.7%)
doi:10.1371/journal.pone.0088315.t004
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praziquantel and albendazole. This study, however, confirms that
the safety of the two drugs even when co-administered.
Approximately 6% of the children interviewed reported experi-
encing severe AEs related to the medications. Therefore, it is
imperative that preventive chemotherapy intervention pro-
grammes put in place surveillance measures in order to ensure
timely detection, management and reporting of potential life-
threatening AEs. The current study adds to the evidence base that
dual administration of albendazole and praziquantel in school-
based MDA is safe with only mild adverse events (AEs) noted.
Acknowledgments
The Matuga District Health Management Team (DHMT) is thanked for
its support of the research project. The teachers, parents and pupils of the
study schools are thanked for their cooperation. We are grateful to the
Director, KEMRI, for granting us the permission to publish this paper.
Author Contributions
Conceived and designed the experiments: SMN MJB. Performed the
experiments: SMN FSB. Analyzed the data: SMN PMN. Wrote the paper:
SMN PMN. Critically revised the manuscript for intellectual content:
MTM MJB.
References
1. World Health Organization (2002) Prevention and control of schistosomiasis and
soil-transmitted helminthiasis: report of a WHO expert committee. In: WHO
Technical Report Series No 912. Geneva. 349 p.
2. World Health Organization (2005) Programme Report no. 17 - Seventeenth
Programme Report of the UNICEF/UNDP/World Bank/WHO Special
Programme for Research & Training in Tropical Diseases. Geneva: WHO,
433 p.
3. Muchiri EM, Ouma JH, King CH (1996) Dynamics and control of Schistosoma
haematobium transmission in Kenya: an overview of the Msambweni Project. Am J
Trop Med Hyg. 55(5 Suppl): 127–134.
4. Brooker S, Peshu N, Warn PA, Mosobo M, Guyatt HL, et al (1999) The
epidemiology of hookworm infection and its contribution to anaemia among
pre-school children on the Kenyan coast. Trans R Soc Trop Med Hyg. 93(3):
240–246.
5. Wiest PM (1996) The epidemiology of morbidity of schistosomiasis. Parasitol
Today. 12(6): 215–220.
6. Fenwick A, Savioli L, Engels D, Bergquist RN, Todd HM (2003) Drugs for the
control of parasitic diseases: current status and development in schistosomiasis.
Trends Parasitol. 19(11): 509–515.
7. Kabatereine NB, Brooker S, Koukounar A, Kazibwe F, Tukahebwa E, et al
(2007) Impact of a national helminth control programme on infection and
morbidity in Ugandan schoolchildren. Bull World Health Organ. 85: 91–99.
8. Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y, et al (2007)
Schistosoma haematobium infection and morbidity before and after large-scale
administration of praziquantel in Burkina Faso. J Infect Dis 196: 659–669.
9. Montresor A, Crompton DW, Gyorkos TW, Savioli L (2002) Helminth control
in school age children: a guide for managers of control programmes Geneva:
World Health Organization.238 p.
10. Southgate VR, Tchuem R, Tchuem LA, Rollinson D, Hagan P (2005) Towards
control of schistosomiasis in sub-Saharan Africa. J Helminthol. 79: 181–185.
11. Kabatereine NB, Tukahebwa EM, Kazibwe F, Namwanje H, Zaramba S, et al
(2006) Progress towards country-wide control of schistosomiasis and soil-
transmitted helminthiasis in Uganda. Trans R Soc Trop Med Hyg 100: 208–15.
12. Anderson RM, May RM (1985) Helminth infections of humans: mathematical
models, population dynamics, and control. Adv Parasitol. 24: 1–11.
13. Stothard JR, French MD, Khamis S, Basa´nez M, Rollinson D (2009) The
epidemiology and control of urogenital schistosomiasis and soil-transmitted
helminthiasis in schoolchildren on Unguja Island, Zanzibar. Trans R Soc Trop
Med Hyg. 103: 1031–1044.
14. Njenga SM, Mwandawiro CS, Muniu E, Mwanje TM, Haji MF, et al (2011)
Adult population as potential reservoir of NTD infections in rural villages of
Kwale district, Coastal Kenya: implications for preventive chemotherapy
interventions policy. Parasit Vectors, 4:175: 3–4.
15. Makau JK, Muhoho N, Awazawa T, Njomo D, Mukoko DA, et al (2004)
Integrated parasite control: Effects or DEC-Albendazole antifilarial regimen on
soil-transmitted helminths infection in Kwale District, coastal Kenya. In 25th
African Health Sciences Congress; Nairobi. Abstract B/022/04.
16. Pullan RL, Gething PW, Smith JL, Mwandawiro CS, Sturrock HJW, et al (2011)
Spatial Modelling of Soil-Transmitted Helminth Infections in Kenya: A Disease
Control Planning Tool. PLoS Negl Trop Dis 5(2): 4–9.
17. Kenya National Bureau of Statistics (2010) 2009 Kenyan Population and
Housing Census Report. Nairobi: KNBS.
18. World Health Organization. (2006) Preventive chemotherapy in human
helminthiasis: coordinated use of anthelminthic drugs in control interventions:
a manual for health professionals and programme managers.
19. World Health Organization. (2011) Assuring safety of preventive chemotherapy
interventions for the control of neglected tropical diseases, 1–54.
20. Adoubryn KD, Kouadio-Yapo CG, Ouhon J, Aka NA, Bintto F, et al (2012)
Intestinal parasites in children in Biankouma, Ivory Coast (mountaineous
western region): efficacy and safety of praziquantel and albendazole. Med Sante
Trop. 22(2): 170–6.
21. N’Goran EK, Gnaka HN, Tanner M, Utzinger J (2003) Efficacy and side-effects
of two praziquantel treatments against Schistosoma haematobium infection, among
schoolchildren from Coˆte d’Ivoire. Ann Trop Med Parasitol. 97: 37–51.
22. Raso G, N’Goran KE, Toty A, Luginbu¨hl A, Adjoua AC, et al (2004) Efficacy
and side effects of praziquantel against Schistosoma mansoni in a community of
western Coˆte d’Ivoire. T Roy Soc Trop Med H. 98(1): 18–27.
23. Erko B, Degarege A, Tadesse K, Mathiwos A, Legesse M. (2012) Efficacy and
side effects of praziquantel in the treatment of Schistosoma mansoni in
schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern
Ethiopia. Asian Pac J Trop Biomed. 2(3): 235–9.
24. Horton J (2000) Albendazole: a review of anthelmintic efficacy and safety in
humans. Parasitology. 121: S113–S132.
25. Berhe N, Gundersen SG, Abebe F, Birrie H, Medhin G, et al (1999)
Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads
and morbidity in primary school children in north-east Ethiopia. Acta Trop. 72:
53–63.
26. Jaoko WG, Muchemi G, Oguya FO (1996) Praziquantel side effects during
treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East Afr Med
J. 73: p. 499–501.
27. Njomo DW, Tomono N, Muhoho N, Mitsui Y, Josyline CK, et al (2010) The
adverse effects of albendazole and praziquantel in mass drug administration by
trained schoolteachers. African Journal of Health Sciences. 17: 3–4.
28. Olds GR, King C, Hewlett J, Olveda R, Wu G, et al (1999) Double-blind
placebo-controlled study of concurrent administration of albendazole and
praziquantel in schoolchildren w with schistosomiasis and geohelminths. J Infect
Dis 179(4): 996–1003.
29. Mohammed KA, Haji HJ, Gabrielli AF, Mubila L, Biswas G, et al (2008) Triple
Co-Administration of Ivermectin, Albendazole and Praziquantel in Zanzibar: A
Safety Study. PLoS Negl Trop Dis. 2(1): 4–5.
Adverse Events of Albendazole and Praziquantel
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e88315
